FDA issues new guidance for pharma on discussing unapproved drugs with payors
read at Endpoints ↗RegulatoryNeutral
The FDA has released guidance aimed at biopharma companies that are preparing to launch new therapies before they receive formal approval.
The advice focuses on how companies can inform health-plan payors about upcoming products without making inaccurate claims or violating regulations.
By following the recommendations, firms can help payors anticipate future treatments while staying within FDA rules, reducing the risk of enforcement actions.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “FDA guides pharma on explaining unapproved drugs to payors”
read at Endpoints ↗86 words · retrieved Jun 3
comments(0)
5-min edit window · permanent after that